Novartis & Astex v. Natco Pharma: KISQALI Ribociclib Patent Dispute Dismissed With Prejudice
Novartis AG and Astex Therapeutics Ltd. filed suit against Natco Pharma in the District of Delaware, asserting two patents covering ribociclib — the active ingredient in the CDK4/6 inhibitor KISQALI. The parties jointly stipulated to dismissal with prejudice after 230 days, with each side bearing its own legal costs.
KISQALI Generic Entry Dispute Ends in Stipulated Dismissal With Prejudice
On September 13, 2024, Novartis AG and Astex Therapeutics Ltd. filed suit against Natco Pharma Ltd., Natco Pharma Inc., and Natco Pharma USA LLC in the U.S. District Court for the District of Delaware. The action, assigned to Judge Jennifer L. Hall, alleged infringement of two patents — US9193732B2 and US9868739B2 — both directed to ribociclib, the CDK4/6 inhibitor marketed by Novartis as KISQALI and the KISQALI FEMARA Co-Pack. Natco’s ANDA filing for generic 200 mg ribociclib tablets triggered the statutory 45-day litigation window.
The case concluded on May 1, 2025, when the parties filed a joint stipulation dismissing all claims with prejudice under Federal Rule of Civil Procedure 41(a)(1)(A)(ii). The dismissal with prejudice constitutes a final adjudication on the merits for res judicata purposes, meaning Novartis and Astex are permanently barred from reasserting these specific patent claims against Natco’s proposed generic product. Notably, each party agreed to bear its own attorneys’ fees and costs, suggesting a negotiated resolution rather than a concession by either side.
A 230-day resolution is notably swift for Hatch-Waxman litigation in Delaware, where cases regularly extend two to three years. The symmetric cost arrangement — neither side paying the other — is consistent with a commercial settlement, potentially involving a licensing agreement or a negotiated market entry date for Natco’s generic, though no such terms appear in the public record. The specific trigger for early resolution and any agreed-upon generic launch terms remain undisclosed.
Filing to Dismissed with Prejudice in 230 days
230 days — resolved faster than the median ANDA patent case in Delaware, which typically runs 2–3 years to trial
Dismissed with prejudice: what the stipulated termination means for both parties
Rule 41 dismissal with prejudice — a final, permanent bar on re-filing
A dismissal with prejudice under Fed. R. Civ. P. 41(a)(1)(A)(ii) is a stipulated, court-endorsed termination that carries the same res judicata effect as a judgment on the merits. Novartis and Astex cannot re-assert US9193732B2 or US9868739B2 against Natco’s 200 mg ribociclib ANDA product in any subsequent U.S. district court action. The finality is mutual and immediate.
Permanent dismissal — no re-filingNovartis and Astex permanently relinquish these claims against Natco
By dismissing with prejudice, Novartis and Astex have foreclosed their ability to use US9193732B2 and US9868739B2 as litigation leverage against Natco specifically. The patents themselves remain valid and enforceable against other potential generic entrants. The symmetric cost arrangement suggests Novartis may have obtained something of commercial value in return — potentially a delayed or licensed entry — though this is not confirmed by the public record.
Claims extinguished vs. Natco onlyNatco clears these two patent claims — path to market depends on undisclosed terms
Natco cannot be sued again under US9193732B2 or US9868739B2 in relation to its ANDA product. Whether Natco secured an agreed launch date, a license, or simply a litigation exit is not disclosed. The absence of a cost award to Natco suggests the resolution was collaborative rather than a capitulation by Novartis. Other Paragraph IV certifications or Orange Book patents could still constrain Natco’s generic launch timeline.
Protected from re-suit on these patentsCDK4/6 inhibitor generics: settlement signals active IP management around KISQALI
KISQALI (ribociclib) is a major oncology asset. A swift, negotiated dismissal after only 230 days is consistent with Novartis actively managing the competitive landscape through licensing rather than prolonged litigation. Other generic manufacturers targeting KISQALI should anticipate a well-defended Orange Book position and should conduct thorough FTO analysis across Novartis’s broader ribociclib patent estate before committing ANDA resources.
Monitor broader KISQALI patent estateFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Novartis, AG | Company | Pharmaceutical innovator and oncology IP licensor — holder of US9193732B2 and US9868739B2 covering ribociclibSearch in Eureka ↗ |
| Co-Plaintiff | Astex Therapeutics, Ltd. | Company | Search in Eureka ↗ |
| Defendant | Natco Pharma, Ltd. | Company | Indian generic pharmaceutical manufacturer and U.S. affiliates seeking ANDA approval for 200 mg ribociclib tabletsSearch in Eureka ↗ |
| Co-Defendant | Natco Pharma USA, LLC | Company | Search in Eureka ↗ |
| Co-Defendant | Natco Pharma, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Alexandra M. Joyce | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff law firm | McCarter & English LLP | Law Firm | Representing Novartis, AGSearch in Eureka ↗ |
| Defendant counsel | Kelly E. Farnan | Attorney | Counsel for Natco Pharma, Ltd.Search in Eureka ↗ |
| Defendant law firm | Richards Layton & Finger PA | Law Firm | Representing Natco Pharma, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge Jennifer L. Hall | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulation recites a Rule 41(a)(1)(A)(ii) dismissal — the procedural vehicle requiring both parties’ signatures, making it self-executing without court order. The ‘with prejudice’ designation is the operative commercial term: it eliminates any future infringement claim by these plaintiffs against this defendant on the two asserted patents. The mutual cost-bearing clause is notable; it suggests neither party viewed itself as the litigation loser, and is consistent with a parallel commercial arrangement reached outside the pleadings.
US9193732B2 & US9868739B2 — Ribociclib CDK4/6 Inhibitor Patents
US9193732B2 and US9868739B2 both protect aspects of ribociclib, a selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor discovered in collaboration between Novartis and Astex Therapeutics. US9193732B2 was prosecuted under application US13/882353 and is understood to cover the core ribociclib compound; US9868739B2, prosecuted under US14/887790, covers formulations and/or related methods of use. Together, these patents anchor Novartis’s Orange Book position for KISQALI, a first-line treatment for HR+/HER2- advanced breast cancer.
KISQALI generated substantial global revenues, making its Orange Book-listed patents prime ANDA litigation targets. The two asserted patents represent Novartis’s compound and formulation layers of protection — a common dual-assertion strategy in Hatch-Waxman cases designed to raise the litigation burden on generic challengers. Co-ownership by Astex Therapeutics, which co-discovered ribociclib, complicates licensing negotiations and means any generic entrant must secure freedom from both parties. Competitors holding or seeking KISQALI ANDA approvals should map the remaining listed patents carefully.
Should your team run an FTO analysis against US9193732B2 and US9868739B2?
Any company developing, manufacturing, or seeking ANDA approval for ribociclib tablets — including 200 mg immediate-release formulations — should treat this case as a signal, not a clearance. The dismissal with prejudice protects Natco specifically; it creates no freedom-to-operate for other generic manufacturers. Formulators, CMOs, and distributors handling ribociclib API or finished-dose products are squarely within the enforcement scope of these patents and of any additional Novartis Orange Book listings.
PatSnap Eureka’s FTO Search Agent can map the full ribociclib patent family across US9193732B2 and US9868739B2, identify continuations, divisionals, and Orange Book co-listings, and flag claim scope that could intersect with proposed generic formulations. R&D teams can generate a first-pass FTO landscape in hours rather than weeks, highlighting claim elements most relevant to generic compound, polymorph, and dosing-method risks before committing to an ANDA filing strategy.
Run a freedom-to-operate analysis on US9193732B2 to assess your product’s exposure
Run FTO in Eureka →Similar CDK4/6 Inhibitor & Hatch-Waxman ANDA Cases in Delaware
Explore related ANDA patent infringement cases involving CDK4/6 inhibitors and oncology small-molecule drugs litigated in the District of Delaware.
What this case signals for the CDK4/6 inhibitor and oncology generics IP landscape
A fast, bilateral dismissal in a high-value oncology ANDA case rarely happens without commercial drivers that don’t appear in the public docket.
Symmetric cost orders in ANDA dismissals typically signal a negotiated deal
When neither party is awarded fees and the case resolves in under eight months, the most commercially rational explanation is a settlement — potentially a licensed entry date for Natco. Generic manufacturers and their investors should watch for FDA tentative approval timelines and any 180-day exclusivity triggers.
Dismissal with prejudice leaves other Natco patent exposure intact
The preclusion effect applies only to US9193732B2 and US9868739B2. Novartis holds additional Orange Book-listed patents for ribociclib formulations and methods of treatment. Natco’s ANDA may still face separate litigation on any remaining listed patents, and any would-be second filer faces no estoppel benefit from this dismissal.
Novartis v Natco — key questions answered
The dismissal with prejudice under Rule 41(a)(1)(A)(ii) means Novartis and Astex Therapeutics are permanently barred from suing Natco on US9193732B2 and US9868739B2 for its ANDA ribociclib product. The patents themselves remain valid and can still be enforced against other generic manufacturers. It does not confer freedom-to-operate on any other ANDA filer.
Novartis and Astex Therapeutics asserted US9193732B2 (application US13/882353) and US9868739B2 (application US14/887790). Both patents cover aspects of ribociclib, the CDK4/6 inhibitor marketed as KISQALI for HR+/HER2- advanced breast cancer. The case involved Natco’s ANDA for generic 200 mg ribociclib tablets and the KISQALI FEMARA Co-Pack.
At 230 days, the case resolved well below the typical 2–3 year Delaware ANDA litigation timeline. The mutual cost-bearing arrangement and stipulated dismissal are consistent with a commercial settlement — potentially a licensing agreement or agreed generic entry date — reached outside the litigation. The specific terms of any such arrangement are not disclosed in the public docket.
No. The preclusion effect of the dismissal with prejudice applies only to Natco Pharma Ltd., Natco Pharma Inc., and Natco Pharma USA LLC in relation to these two specific patents. Other generic manufacturers targeting ribociclib remain fully exposed to infringement claims under US9193732B2, US9868739B2, and any other Orange Book-listed KISQALI patents. Each ANDA filer must independently assess its patent risk.
Astex Therapeutics Ltd. co-discovered ribociclib with Novartis and holds rights — co-ownership or exclusive licensing rights — in the asserted patents, requiring its joinder as co-plaintiff. Practically, this means any licensing resolution requires agreement from both Novartis and Astex. Generic manufacturers and their legal teams should account for this two-party consent requirement when modelling licensing cost and complexity.
PatSnap Eureka searches patents and litigation data to answer instantly.